Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH003 monotherapy in advanced solid tumors
NCT05017623Phase 1Completed
- Sponsor
- Eucure Biopharma
- Start
- Aug 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ciltistotug in solid tumor, sponsored by Eucure Biopharma. Primary endpoints: Adverse events (AEs) at 1 year and Maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) at 1 year. Started Aug 2021; status: completed.
02
Drugs
ciltistotug
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05017623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017623.